Kymera Therapeutics, Inc. (KYMR): Results of Operations and Financial Condition
Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data e
How this was made
The 30-second read
Why it matters
The most decision-relevant update is the pull-forward of KT-621 BROADEN2 topline timing to year-end 2026 and an earlier-than-anticipated Phase 3 start, alongside cash runway disclosure and partnered-program milestone payments.
Market read
For KYMR, the filing updates the near-term clinical catalyst calendar (year-end 2026 topline for KT-621 BROADEN2) and reinforces balance-sheet runway (cash of $1.5B as of June 30, 2026).
What to watch
The filing emphasizes expected data windows (year-end 2026, late 2027, 4Q26) rather than results; traders should weigh the probability of schedule slippage and the absence of topline efficacy/safety numbers in this release.
Background
This is Kymera Therapeutics’ SEC Form 8-K (Item 2.02) with Q2 2026 financial results and a business update on its immunology pipeline.
Ticker impact
Kymera’s 8-K reports Q2 2026 results plus pipeline updates, including accelerated enrollment completion for KT-621 BROADEN2 and a pulled-forward year-end 2026 topline readout.
Bias toward positive near-term sentiment as the year-end 2026 topline and mid-2027 Phase 3 initiation are pulled forward versus prior expectations.
The filing explicitly states enrollment completion nearly six months ahead and accelerates topline timing to year-end 2026, which can re-rate clinical catalysts and risk timing for a clinical-stage biotech.
Market effects
Supports sentiment for oral immunology degrader platforms and STAT6/IRF5 pathway programs, but impact is company-specific rather than a broad sector reset.
Limited, as the update is primarily US-listed company execution and global trial enrollment progress.
Moderate for global immunology investors due to Japan-specific KT-621 Phase 1 data and worldwide Type 2 disease framing, but no new regulatory or partnership expansion beyond milestones.
Counterpoint
Accelerated enrollment does not guarantee efficacy or safety outcomes; the market may overreact to timeline progress without new efficacy data.
Key entities
- companyKymera Therapeutics, Inc.
NASDAQ-listed clinical-stage biopharmaceutical company advancing oral small-molecule degrader programs.
- programKT-621 (STAT6)
Once-daily oral STAT6 degrader in Phase 2b for atopic dermatitis and asthma; BROADEN2 enrollment completed nearly six months ahead.
- programKT-579 (IRF5)
Oral IRF5 degrader in Phase 1 healthy volunteer testing with data expected in 4Q26.
- partnerSanofi
Partner leading development for KT-485 (IRAK4) under collaboration; first participant dosing triggered a $20 million milestone payment to Kymera.
- partnerGilead Sciences
Exercised an option to exclusively license KT-200, triggering a $45 million milestone payment to Kymera.
